Clinical trial
A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal…
NCT00401479 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00401479 |
|---|---|
| Title | A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers |
| Official title | An Exploratory Phase I Study in Healthy Volunteers of GI Transit Following Administration of the ß3-Adrenergic Receptor Agonist, Solabegron (Study B3I106248) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Irritable Bowel Syndrome (IBS) |
| Intervention type | Drug |
| Interventions | Placebo, Solabegron (GW427353) |
| Enrollment | 36 |
| Start date | Oct 1, 2006 |
| First posted | Nov 20, 2006 |
| Last update posted | Oct 16, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: